PharmaMar's Zepsyre misses in Phase III for platinum-resistant ovarian cancer

PharmaMar S.A. (Madrid:PHM) said Zepsyre lurbinectedin (PM01183, PM1183) missed the primary endpoint of improving progression-free survival (PFS) vs. topotecan or pegylated liposomal doxorubicin in the Phase

Read the full 263 word article

User Sign In